JN BIOTECH ApS
CVR 25325001 · Private limited company (ApS) · Active · Low risk
JN BIOTECH ApS is a Private limited company (ApS), founded on , based in Hellerup. The company is registered in the industry andre personlige serviceydelser i.a.n.. Our model estimates a bankruptcy risk of 0.2% over the next 12 months, which is 0.2 times the average for Danish companies. 20 annual reports have been published. The latest annual report (30 Jun 2025) shows equity of DKK 821k and a net result of DKK 104k. CEO: Jens Bredal Nielsen.
Bankruptcy risk for JN BIOTECH ApS
0.2 × the average (1.41%) · higher risk than 49% of active Danish companies
Increases the risk
Reduces the risk
The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.
Company details
- CVR number
- 25325001
- Status
- Active
- Company type
- Private limited company (ApS)
- Founded
- (26 years)
- Address
- Tuborg Boulevard 9, 3. tv
2900 Hellerup - Municipality
- Gentofte
- Industry
- Andre personlige serviceydelser i.a.n. (969900)
Bankruptcies in the industry: Frisørsaloner - Share capital
- DKK 225k
- Employees
- 1 (2006)
- Auditor
- Beierholm
- Audit opted out
- Yes
Warning signs
| Annual reports filed late | 0 of 24 |
| Missing annual report | No |
| Negative equity | No |
| Equity ratio | 61.8% |
| Current ratio | 262% |
| Moves (last 2 years) | 0 |
| CEO changes in total | 4 |
| CEO's previous bankruptcies | 0 |
| Other companies at the address | 3 |
| Going-concern uncertainty | No |
Financials and key figures
| Financial year | 2025 | 2024 |
|---|---|---|
| Gross profit | DKK 90k | DKK 28k |
| Net profit | DKK 104k | DKK 61k |
| Equity | DKK 821k | DKK 717k |
| Total assets | DKK 1.3m | DKK 1.3m |
| Cash | DKK 9,113 | – |
| Short-term debt | DKK 507k | – |
| Tax owed | DKK 31k | – |
| Avg. employees | 0 | – |
Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · Beierholm.
Filed annual reports
| Reporting period | Published | Days after period end | |
|---|---|---|---|
| 1 Jul 2024 – 30 Jun 2025 | 161 | ||
| 1 Jul 2023 – 30 Jun 2024 | 150 | ||
| 1 Jul 2022 – 30 Jun 2023 | 171 | ||
| 1 Jul 2021 – 30 Jun 2022 | 147 | ||
| 1 Jul 2020 – 30 Jun 2021 | 163 | ||
| 1 Jan 2019 – 30 Jun 2020 | 154 | ||
| 1 Jan 2018 – 31 Dec 2018 | 147 | ||
| 1 Jan 2017 – 31 Dec 2017 | 171 | ||
| 1 Jan 2016 – 31 Dec 2016 | 135 | ||
| 1 Jan 2015 – 31 Dec 2015 | 125 | ||
| 1 Jan 2014 – 31 Dec 2014 | 149 | ||
| 1 Jan 2013 – 31 Dec 2013 | 134 | ||
| 1 Jan 2012 – 31 Dec 2012 | 84 | ||
| 1 Jan 2011 – 31 Dec 2011 | 169 | ||
| 1 Jan 2010 – 31 Dec 2010 | 160 | ||
| 1 Jan 2009 – 31 Dec 2009 | 159 | ||
| 1 Jan 2008 – 31 Dec 2008 | 145 | ||
| 1 Oct 2006 – 30 Sep 2007 | 164 | ||
| 1 Oct 2005 – 30 Sep 2006 | 156 | ||
| 1 Oct 2004 – 30 Sep 2005 | 152 |
The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.
Management, owners and auditor
| Role | Name | From | To |
|---|---|---|---|
| CEO | Jens Bredal Nielsen | Current | |
| CEO | Jens Bredal Nielsen | ||
| CEO | Jytte Nielsen | ||
| Owner (90%) | JBN Biotech ApS | Current | |
| Owner (100%) | Jens Bredal Nielsen | ||
| Auditor | Hans Munkebo Christiansen | ||
| Auditor | PricewaterhouseCoopers, Statsautoriseret Revisionsinteressentskab | ||
| Auditor | Jacob Fromm Christiansen | ||
| Auditor | PRICEWATERHOUSECOOPERS SERVICES STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Auditor | BEIERHOLM, STATSAUTORISERET REVISIONSAKTIESELSKAB | ||
| Auditor | Beierholm Godkendt Revisionspartnerselskab | ||
| Founder | Jens Bredal Nielsen | Current |
The CEOs' other companies
Jens Bredal Nielsen – 11 other companies, of which 2 bankrupt
- FLUXOME SCIENCES A/S Bankrupt 28 Nov 2012
- GENECARE ApS Bankrupt 29 Nov 2007
- ACCELERACE MANAGEMENT A/S Active
- BII Catalyst AIFM ApS Active
- FLUXOME HOLDING ApS Opløst
- GENECARE DEVELOPMENT ApS Compulsorily dissolved
- HBO. HEDENSTED ApS Fusioneret
- HEDENSTED BOGTRYKKERI ApS Opløst
- JBN Biotech ApS Active
- MYCOTEQ A/S Opløst
- N&N BIOTECH ApS Opløst
Jytte Nielsen – 3 other companies
- A/S TRYKCENTRALEN 1969 Opløst
- HEDENSTED BOGTRYKKERI ApS Opløst
- OTM AVISTRYK A/S Active
Address history (2 moves)
| Tuborg Boulevard 9, 3. tv, 2900 Hellerup | |
| c/o Jytte Nielsen, Søparken 127, 5260 Odense S | |
| c/o Jens Bredal Nielsen, Hans Bruuns Vej 8, 2920 Charlottenlund |
Employees per year
Other companies at the same address
- ATECH INGENIØRFIRMA ApS Active
- JBN Biotech ApS Active
- SPECIALLÆGESELSKABET NIELS HYLDEBRANDT ApS Opløst
Similar companies in Gentofte
- PawPal ApS Charlottenlund
- Hales Dog Daycare ApS Hellerup
- Æstetik - medicinsk tatovering ApS Hellerup
- Atelier petit ApS Hellerup
- Dinas energi ApS Hellerup
- Lev for helvede ApS Charlottenlund
- Hundens Univers ApS Charlottenlund
- By Komi ApS Hellerup
- HFJ2020 ApS Gentofte
- NONA ApS Hellerup
- The Assana ApS Charlottenlund
- FAMOBA ApS Charlottenlund
Questions and answers about JN BIOTECH ApS
Has JN BIOTECH ApS gone bankrupt?
No, JN BIOTECH ApS is not registered as bankrupt in the CVR register. Its status is: active.
What is the bankruptcy risk of JN BIOTECH ApS?
Our model estimates a bankruptcy risk of 0.2% over the next 12 months (low risk), which is 0.2 times the average for Danish companies.
Who is the CEO of JN BIOTECH ApS?
Jens Bredal Nielsen is the CEO of JN BIOTECH ApS.
Who is the auditor of JN BIOTECH ApS?
JN BIOTECH ApS most recently used Beierholm.
When was JN BIOTECH ApS founded?
JN BIOTECH ApS was founded on 19 April 2000.
What is the equity of JN BIOTECH ApS?
Equity was DKK 821k according to the annual report for the period ending 30 June 2025.
Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.